全文获取类型
收费全文 | 222篇 |
免费 | 13篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 5篇 |
妇产科学 | 4篇 |
基础医学 | 20篇 |
口腔科学 | 1篇 |
临床医学 | 24篇 |
内科学 | 43篇 |
皮肤病学 | 8篇 |
神经病学 | 20篇 |
特种医学 | 12篇 |
外科学 | 26篇 |
综合类 | 1篇 |
预防医学 | 4篇 |
眼科学 | 7篇 |
药学 | 49篇 |
中国医学 | 2篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 1篇 |
2018年 | 13篇 |
2017年 | 5篇 |
2016年 | 6篇 |
2015年 | 21篇 |
2014年 | 22篇 |
2013年 | 19篇 |
2012年 | 11篇 |
2011年 | 16篇 |
2010年 | 8篇 |
2009年 | 3篇 |
2008年 | 3篇 |
2007年 | 10篇 |
2006年 | 7篇 |
2005年 | 12篇 |
2004年 | 8篇 |
2003年 | 11篇 |
2002年 | 9篇 |
2000年 | 5篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1993年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1980年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有237条查询结果,搜索用时 31 毫秒
1.
2.
3.
Danial E. Baker 《Hospital pharmacy》2014,49(11):999-1000
4.
5.
Jasbir Makker Hassan Tariq Kishore Kumar Madhavi Ravi Danial Haris Shaikh Vivien Leung Umar Hayat Muhammad T Hassan Harish Patel Suresh Nayudu Sridhar Chilimuri 《World journal of gastroenterology : WJG》2021,27(6):523-533
BACKGROUND Nonalcoholic fatty liver disease(NAFLD)and type-2 diabetes mellitus(T2DM)have an intricate bidirectional relationship.Individuals with T2DM,not only have a higher prevalence of non-alcoholic steatosis,but also carry a higher risk of progression to nonalcoholic steatohepatitis.Experts still differ in their recommendations of screening for NAFLD among patients with T2DM.AIM To study the prevalence of NAFLD and advanced fibrosis among our patient population with T2DM.METHODS During the study period(November 2018 to January 2020),59 adult patients with T2DM and 26 non-diabetic control group individuals were recruited prospectively.Patients with known significant liver disease and alcohol use were excluded.Demographic data and lab parameters were recorded.Liver elastography was performed in all patients.RESULTS In the study group comprised of patients with T2DM and normal alanine aminotransferase levels(mean 17.8±7 U/L),81%had hepatic steatosis as diagnosed by elastography.Advanced hepatic fibrosis(stage F3 or F4)was present in 12%of patients with T2DM as compared to none in the control group.Patients with T2DM also had higher number of individuals with grade 3 steatosis[45.8%vs 11.5%,(P<0.00001)and metabolic syndrome(84.7%vs 11.5%,P<0.00001)].CONCLUSION A significant number of patients with T2DM,despite having normal transaminase levels,have NAFLD,grade 3 steatosis and advanced hepatic fibrosis as measured by liver elastography. 相似文献
6.
Muhammad Umer Siddiqui Ahmed K. Pasha Ibtisam Rauf Justin Z. Lee Muhammad Danial Siddiqui Youssef Yaacoub Mohammad Reza Movahed 《Clinical Medicine & Research》2021,19(1):19
Objective: The study objective was to determine if peri-operative bridging anticoagulation in patients with atrial fibrillation is beneficial or harmful.Design: Systematic review and meta-analysis.Setting: Inpatient or in-hospital setting.Participants: Adults with atrial fibrillation having a CHADS2 score >1 undergoing elective surgical procedure on anticoagulation.Methods: A systemic search of multiple databases (Cochrane, Medline, PubMed) was performed regarding studies conducted on efficacy and safety of perioperative bridging anticoagulation in patients with atrial fibrillation. Studies identified were reviewed by two authors individually before inclusion. The results were then pooled using Review Manager to determine the combined effect. Stroke/systemic embolism was considered as the primary efficacy outcome. Major bleeding was the primary safety outcome.Results: The systematic search revealed 108 potential articles. The full texts of 28 articles were retrieved for assessment of eligibility. After full text review, 25 articles were excluded. Three articles met inclusion criteria. No significant difference in stroke/systemic embolism with bridging anticoagulation was noted (risk ratio, 1.25-95% confidence interval [CI], 0.55–2.85). Bridging was associated with significantly higher risk of major bleeding (risk ratio, 3.29-95% CI, 2.25–4.81).Conclusion: An individualized approach is required when initiating peri-operative bridging anticoagulation. There is certainly a higher risk of bleeding with bridging anticoagulation and no difference in stroke/systemic embolism. However, the results cannot be extrapolated to patients who have valvular atrial fibrillation or CHADS2 score of 5 or greater. 相似文献
7.
8.
9.
10.